FDA Grants Breakthrough Therapy Designation for Concentric Analgesics’ CA-008 in Post-Surgical PainAddictions, Biopharmaceutical, Breakthrough Therapy Designation, Fast Track Designation, FDA/Regulatory, First-In-Class, Opioids, Post-Surgery Pain ReliefConcentric Analgesics Inc. announced today that the clinical-stage biopharmaceutical company received Breakthrough Therapy designation from the U.S. Food and Drug Administration for CA-008 in post-surgical pain. Read more September 11, 2018/by Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Business Wire2018-09-11 08:30:032018-09-12 13:40:49FDA Grants Breakthrough Therapy Designation for Concentric Analgesics’ CA-008 in Post-Surgical Pain
